Veru Inc. (NASDAQ: VERU) Q2 2025 Results Conference Call May 8, 2025 8:00 AM ET Company Participants Sam Fisch - Executive Director, Investor Relations and Corporate Communications Mitchell ...

Veru Inc. announced positive topline safety data from its Phase 2b QUALITY clinical study, which evaluates the combination of enobosarm and semaglutide for weight management in older patients.

Novo Nordisk NOVO.B 2.82% plans to expand access to Wegovy through a collaboration with WeightWatchers, days after ending a partnership with telehealth firm Hims & Hers to sell the weight-loss drug.

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what researchers found.

Veru currently has sufficient drug substance to supply the proposed Phase 2 clinical study. Second Quarter Financial Summary: Fiscal 2025 vs Fiscal 2024 ...

CEO Mitchell Steiner emphasized Veru’s focus on its obesity program, highlighting the positive Phase 2b clinical trial results for enobosarm. This drug, when combined with semaglutide ...

Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, known as Ozempic and Wegovy, according to new research.

Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress May 08, 2025 6:30 AM ET Veru Inc. (VERU) ...

Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared ...

Hims, Ro and LifeMD will soon start selling Wegovy at a reduced price of $499 per month.

The weight loss drug Wegovy treated a serious form of liver disease in about two-thirds of patients in a major clinical trial, according to the findings published Wednesday in the New England ...